AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31043169 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial assessment by physiotherapists
Number of subjects: 55
Study 31043169 — intervention group
Group type: COMPARATOR
Intervention: Standard practice with initial GP assessment
Number of subjects: 55
Study 27121863 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 50
Study 27121863 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 25283137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of chloral hydrate (CH) for five consecutive days
Number of subjects: 8
Study 25283137 — intervention group
Group type: COMPARATOR
Intervention: 1.5 μg/kg of chloral hydrate (CH) for five consecutive days (environmental dose)
Number of subjects: 8
Study 23348836 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-fluorouracil
Number of subjects: 1131
Study 23348836 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Number of subjects: 1131
Study 23348836 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 1131
Study 20797824 — intervention group
Group type: EXPERIMENTAL
Intervention: Short neoadjuvant hormonal therapy (4 months; Arm 1)
Number of subjects: 261
Study 20797824 — intervention group
Group type: EXPERIMENTAL
Intervention: Long neoadjuvant hormonal therapy (8 months; Arm 2)
Number of subjects: 261
Study 19247758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided block of the brachial plexus using lidocaine 1.5% with epinephrine
Number of subjects: 20
Study 19247758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided block of the brachial plexus
Number of subjects: 20
Study 16890660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) with bacillus Calmette‐Guerin
Number of subjects: 115
Study 16890660 — intervention group
Group type: COMPARATOR
Intervention: Bacillus Calmette‐Guerin (placebo)
Number of subjects: 115
Study 15301635 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg
Number of subjects: 21
Study 15301635 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 21
Study 15301635 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 21
Study 15301635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11165973 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 130
Study 11165973 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 130
Study 9407567 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf
Number of subjects: 16
Study 9407567 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 16
Study 7970086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 18
Study 7970086 — intervention group
Group type: COMPARATOR
Intervention: Control group (protein restriction, antihypertensive therapy)
Number of subjects: 18
Study 7970086 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treatment vs control
Number of subjects: 18
Study 2451494 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate artificial tear preparation
Number of subjects: 0
Study 2451494 — intervention group
Group type: COMPARATOR
Intervention: 1.4% polyvinyl alcohol and 0.5% chlorobutanol artificial tear preparation
Number of subjects: 0
Study 2451494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 0
Study 31702992 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal high-voltage monophasic pulsed currents (HVMPC) treatment (154 μs; 100 Hz; 360 µC/sec; 1.08 C/day) for 50 minutes a day, 5 days per week, for 8 weeks.
Number of subjects: 43
Study 31702992 — intervention group
Group type: COMPARATOR
Intervention: Cathodal high-voltage monophasic pulsed currents (HVMPC) treatment (154 μs; 100 Hz; 360 µC/sec; 1.08 C/day) for 50 minutes a day, 5 days per week, for 8 weeks.
Number of subjects: 43
Study 31702992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham) treatment for 50 minutes a day, 5 days per week, for 8 weeks.
Number of subjects: 43
Study 28445474 — intervention group
Group type: EXPERIMENTAL
Intervention: COACH program (medication reconciliation, patient counselling at discharge, communication to healthcare providers)
Number of subjects: 319
Study 28445474 — intervention group
Group type: EXPERIMENTAL
Intervention: COACH program
Number of subjects: 319
Study 28445474 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 319
Study 26007320 — intervention group
Group type: EXPERIMENTAL
Intervention: Condori red grapes (500 g daily for 8 weeks)
Number of subjects: 69
Study 26007320 — intervention group
Group type: EXPERIMENTAL
Intervention: Shahroodi white grapes (500 g daily for 8 weeks)
Number of subjects: 69
Study 26007320 — intervention group
Group type: COMPARATOR
Intervention: Control group (no grape consumption)
Number of subjects: 69
Study 24001950 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond (self-etching adhesive)
Number of subjects: 67
Study 24001950 — intervention group
Group type: EXPERIMENTAL
Intervention: cfm (3-step HEMA and TEGDMA free etch-and-rinse)
Number of subjects: 67
Study 24001950 — intervention group
Group type: COMPARATOR
Intervention: XP Bond (control HEMA-containing etch-and-rinse adhesive)
Number of subjects: 67
Study 20951420 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite lining
Number of subjects: 80
Study 20951420 — intervention group
Group type: COMPARATOR
Intervention: Glass-ionomer lining
Number of subjects: 80
Study 20951420 — intervention group
Group type: COMPARATOR
Intervention: Unlined
Number of subjects: 80
Study 20951420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity width and C-factor
Number of subjects: 80
Study 20951420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity depth and cusp compliance
Number of subjects: 80
Study 19934458 — intervention group
Group type: EXPERIMENTAL
Intervention: SHIP-DM intervention (6-week structured psychobehavioral education, home glucose monitoring with teletransmission, bilingual nurse telephone counseling for 24 weeks)
Number of subjects: 79
Study 19934458 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention design)
Number of subjects: 79
Study 21959045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus mIFL (irinotecan 125 mg/m², leucovorin 20 mg/m² bolus, 5-fluorouracil 500 mg/m² weekly for four weeks every six weeks)
Number of subjects: 214
Study 21959045 — intervention group
Group type: COMPARATOR
Intervention: mIFL (irinotecan 125 mg/m², leucovorin 20 mg/m² bolus, 5-fluorouracil 500 mg/m² weekly for four weeks every six weeks)
Number of subjects: 214
Study 16156464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation (C-F)
Number of subjects: 116
Study 16156464 — intervention group
Group type: COMPARATOR
Intervention: Uncemented porous fixation (UC-F)
Number of subjects: 116
Study 16156464 — intervention group
Group type: COMPARATOR
Intervention: Uncemented porous hydroxyapatite fixation (UCHA-F)
Number of subjects: 116
Study 12484510 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 5 mg daily (normal dose) in patients with LVH
Number of subjects: 72
Study 12484510 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 2.5 mg daily (half dose) in patients without LVH
Number of subjects: 72
Study 12484510 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of ACE inhibitor in patients with or without LVH
Number of subjects: 72
Study 9771173 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane delivered from a Komesaroff vaporiser
Number of subjects: 19
Study 9771173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow rates of 1, 2 or 3 l.min‐1
Number of subjects: 19
Study 8580391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 671
Study 8580391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study 2653592 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol hydrochloride
Number of subjects: 91
Study 2653592 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 91
Study 383097 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 times a day 3 mg haloperidol (3-day group)
Number of subjects: 30
Study 383097 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg haloperidol only in the evening (1-day group)
Number of subjects: 30
Study 383097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 11312480 — intervention group
Group type: COMPARATOR
Intervention: Control (no antiarrhythmics)
Number of subjects: 400
Study 11312480 — intervention group
Group type: COMPARATOR
Intervention: Magnesium only
Number of subjects: 400
Study 11312480 — intervention group
Group type: COMPARATOR
Intervention: Digoxin only
Number of subjects: 400
Study 11312480 — intervention group
Group type: COMPARATOR
Intervention: Magnesium and digoxin
Number of subjects: 400
Study 11312480 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol only
Number of subjects: 400
Study 11312480 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium and propranolol
Number of subjects: 400
Study 31392827 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban 80 mg qd for 35 to 42 days
Number of subjects: 2781
Study 31392827 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg qd for 10 ± 4 days
Number of subjects: 2781
Study 30293126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg twice daily
Number of subjects: 0
Study 30293126 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted)
Number of subjects: 0
Study 27060958 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory Stimulation Environment (MSSE)
Number of subjects: 22
Study 27060958 — intervention group
Group type: COMPARATOR
Intervention: Individualized Music Sessions
Number of subjects: 22
Study 27060958 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MSSE and Individualized Music Sessions
Number of subjects: 22
Study 25268099 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 54
Study 23170921 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil, midazolam and propofol
Number of subjects: 260
Study 23170921 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl, midazolam and propofol
Number of subjects: 260
Study 20022809 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day orally)
Number of subjects: 172
Study 20022809 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2 intravenously) plus Docetaxel (60 mg/m2 intravenously)
Number of subjects: 172
Study 20022809 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 172
Study 17710370 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine (GlaxoSmithKline Biologicals)
Number of subjects: 299
Study 17710370 — intervention group
Group type: COMPARATOR
Intervention: MMR+V (Priorix and Varilrix vaccines)
Number of subjects: 299
Study 14713758 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoprevention agents
Number of subjects: 0
Study 14713758 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 clinical trials of various agents
Number of subjects: 0
Study 14713758 — intervention group
Group type: COMPARATOR
Intervention: Prostate Cancer Prevention Trial
Number of subjects: 0
Study 14713758 — intervention group
Group type: COMPARATOR
Intervention: Selenium and Vitamin E Cancer Prevention Trial
Number of subjects: 0
Study 11781276 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg daily for 8 weeks
Number of subjects: 28
Study 11781276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9759800 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol)
Number of subjects: 9
Study 9759800 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 9
Study 8588136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin plus mecillinam (A+M)
Number of subjects: 293
Study 8588136 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime followed by cefadroxil
Number of subjects: 293
Study 2483445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine, digitalis, and diuretics
Number of subjects: 0
Study 2483445 — intervention group
Group type: COMPARATOR
Intervention: Placebo, digitalis, and diuretics
Number of subjects: 0
Study 779561 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ounces of ethanol
Number of subjects: 12
Study 779561 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ounces of ethanol
Number of subjects: 12
Study 779561 — intervention group
Group type: COMPARATOR
Intervention: Fresca (control)
Number of subjects: 12
Study 31553471 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 2963
Study 31553471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2963
Study 28698169 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medicine offering (DMO) for 4 weeks
Number of subjects: 109
Study 28698169 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medicine offering (DMO) for 12 weeks
Number of subjects: 109
Study 28698169 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medicine offering (DMO)
Number of subjects: 109
Study 28698169 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 109
Study 26228887 — intervention group
Group type: EXPERIMENTAL
Intervention: HydroCoils
Number of subjects: 66
Study 23207715 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 14
Study 23207715 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study 21561620 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (2.4 g/day of EPA and DHA for 6 weeks)
Number of subjects: 43
Study 21561620 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 43
Study 21561620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of statins and n-3 fatty acids
Number of subjects: 43
Study 21561620 — intervention group
Group type: COMPARATOR
Intervention: Control (soya and corn oil)
Number of subjects: 43
Study 18427130 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipid-lowering strategy
Number of subjects: 1319
Study 18427130 — intervention group
Group type: COMPARATOR
Intervention: Moderate lipid-lowering strategy
Number of subjects: 1319
Study 18427130 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipid-lowering therapy
Number of subjects: 1319
Study 16540826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 30
Study 16540826 — intervention group
Group type: COMPARATOR
Intervention: Stretching and relaxation program (Control)
Number of subjects: 30
Study 12370849 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 9
Study 12370849 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (HCD)
Number of subjects: 9
Study 10325756 — intervention group
Group type: COMPARATOR
Intervention: Once daily growth hormone injections (6 IU/m2/day)
Number of subjects: 19
Study 10325756 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily growth hormone injections (6 IU/m2/day)
Number of subjects: 19
Study 10325756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (once daily and twice daily) with low dose ethinyl oestradiol (0.05 microgram/kg/day, increased to 0.10 microgram/kg/day after 2.25 years)
Number of subjects: 19
Study 7489218 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural spinal cord electrical stimulation (ESES) in addition to best medical treatment
Number of subjects: 120
Study 7489218 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 120
Study 7489218 — intervention group
Group type: EXPERIMENTAL
Intervention: ESES treatment
Number of subjects: 120
Study 1844568 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg per day for 8 weeks)
Number of subjects: 10
Study 1844568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mg per day for 8 weeks)
Number of subjects: 10
Study 6786412 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 percent mannitol solution orally
Number of subjects: 38
Study 6786412 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline via nasogastric tube
Number of subjects: 38
Study 6786412 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 10 percent mannitol and isotonic saline
Number of subjects: 38
Study 29554042 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced whole blood
Number of subjects: 41
Study 29554042 — intervention group
Group type: COMPARATOR
Intervention: Nonleukoreduced whole blood
Number of subjects: 41
Study 29554042 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitation methods
Number of subjects: 41
Study 28024270 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30mg)
Number of subjects: 0
Study 28024270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26306456 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP) for slow VT (CL 400-321 ms) and fast VT (CL 250-320 ms)
Number of subjects: 67
Study 26306456 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing (ATP) in secondary prevention (SP) patients
Number of subjects: 67
Study 23535211 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 59
Study 23535211 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplementation (protein/carbohydrate) during RT
Number of subjects: 59
Study 21632666 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy diet for nine weeks (2.3 MJ/day for seven weeks and two weeks of gradual introduction of normal food) followed by a weight loss maintenance programme
Number of subjects: 63
Study 21632666 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy diet
Number of subjects: 63
Study 21632666 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 63
Study 18842151 — intervention group
Group type: EXPERIMENTAL
Intervention: Large head metal-on-metal total hip arthroplasty (cementless titanium alloy acetabular component with cobalt-chromium liner and cobalt-chromium femoral head varying from 38 to 60 mm)
Number of subjects: 0
Study 18842151 — intervention group
Group type: COMPARATOR
Intervention: 28 mm metal-on-polyethylene total hip arthroplasty (cementless titanium alloy acetabular component with polyethylene liner and 28 mm cobalt-chromium femoral head)
Number of subjects: 0
Study 17238337 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital pen and paper technology for vital sign data capture
Number of subjects: 0
Study 12955414 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 2647
Study 12955414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2647
Study 10626718 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam premedication (2 mg im 30 min before operation)
Number of subjects: 50
Study 10626718 — intervention group
Group type: COMPARATOR
Intervention: Control group (no midazolam premedication)
Number of subjects: 50
Study 10180649 — intervention group
Group type: EXPERIMENTAL
Intervention: Community optometrists
Number of subjects: 0
Study 10180649 — intervention group
Group type: COMPARATOR
Intervention: Hospital ophthalmologists
Number of subjects: 0
Study 10180649 — intervention group
Group type: COMPARATOR
Intervention: Hospital ophthalmologists (assuming 6-month follow-up)
Number of subjects: 0
Study 8204811 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of nitric oxide (NO) at concentrations of 2 to 25 ppm for 6 to 10 minutes
Number of subjects: 7
Study 2454375 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (C)
Number of subjects: 0
Study 28719485 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of heat gel pack after removal of EMLA cream (treatment group)
Number of subjects: 400
Study 28719485 — intervention group
Group type: COMPARATOR
Intervention: No application of heat gel pack (control group)
Number of subjects: 400
Study 26512967 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC3
Number of subjects: 112
Study 26512967 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCG2
Number of subjects: 112
Study 26512967 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of overexpressed ABC-transporters
Number of subjects: 112
Study 24447534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil ODT without water (50 mg)
Number of subjects: 36
Study 24447534 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil ODT with water (50 mg)
Number of subjects: 36
Study 24447534 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal effect on sildenafil ODT
Number of subjects: 36
Study 22978684 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-chlorambucil
Number of subjects: 49
Study 22978684 — intervention group
Group type: COMPARATOR
Intervention: Rituximab alone
Number of subjects: 49
Study 19933411 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 82
Study 19933411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 18164862 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Gy EBRT
Number of subjects: 96
Study 18164862 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy EBRT
Number of subjects: 96
Study 16896965 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/4‐mg gum + 15‐mg patch (G/P)
Number of subjects: 27
Study 16896965 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/4‐mg lozenges + 15‐mg patch (L/P)
Number of subjects: 27
Study 16896965 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler + 15‐mg patch (I/P)
Number of subjects: 27
Study 16896965 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg + 15‐mg patches (P/P)
Number of subjects: 27
Study 16896965 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute‐patch combinations (A/P)
Number of subjects: 27
Study 11889328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (15 microg/kg as a single bolus over 10 mins)
Number of subjects: 55
Study 11889328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol
Number of subjects: 55